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We recently demonstrated that 2,6,diamino-N-([l-(oxotridecyl)-2-piperidinyl]n~ethyl)-hexanamide (NPC 15437) is a selective inhibitor of PKC inter- 
acting at the regulatory domain of the enzyme. To further investigate the interaction of NPC 15437 with PKC we expressed a series of cDNAs 
encoding mutant PKC molecules in COS7 cells. NPC 15437 had no effect on the protein kinase activity of mutants lacking the N-terminal region 
of the Cl domain. Further, NPC 15437 was a competitive inhibitor of the activation of PKCa by phorbol ester and attenuated the binding of 
phorbol ester to the enzyme in intact cells. The present study demonstrates that mutant enzyme constructs can be used to localize the site of interac- 
tion of NPC 15437 with PKC to residues 12-42, which encodes the pseudosubstrate binding domain and part of the first cysteine-rich repeat se- 
quence. 
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1. INTRODUCTION 
The pivotal role of protein kinase C (PKC) in 
regulating a wide variety of transmembrane signal 
transduction events is now widely accepted [1,2]. At 
least seven subtypes of the enzyme exist, each has been 
shown to have distinct properties, ontogenic and tissue 
distributions 131. The amino acid sequences deduced 
from the cDNAs cloned from various species have 
revealed that PKC has three conserved (Cl-C3) and 
four clivergent regions [3]. The availability of recombi- 
nant mutant PKCs has extended earlier biochemical fin- 
dings about the role of these domains [4-61. Thus, 
mutants lacking the Cl domain demonstrate kinase ac- 
tivity independent of phospholipid, calcium, and phor- 
bol ester [4,5]. Protein kinase activity of mutants lack- 
ing the C2 region is much less dependent on calcium 
compared to the wild-type PKC [5]. A PKC mutant 
lacking the C3 region has no protein kinase activity 
under any conditions [4]. Such mutants are also useful 
tools for studies on the sites of interaction of inhibitors 
with the enzyme. 
We have recently reported that 2,6,diamino-N- 
([ I-(oxotridecyl)-2-piperidinyl]methyl)-hexanamide 
(NPC 15437) inhibits PKC by an interaction at the 
regulatory clomain [7]. Further, we demonstrated that 
NPC 15437 is more selective in its inhibition of PKC 
than either H7, staurosporine or sphingosine. In the 
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present study we have expressed a series of cDNAs 
coding for mutant PKCs (Fig. 1) in COST’ cells in order 
to further investigate the inhibitory mechanism of NPC 
15437 against PKC. 
2. MATERIALS AND METHODS 
2.1. Materials 
cDNA encoding bovine PKCol and a series of cDNAs coding for 
mutant PKCs. cloned into the expression vector pcDSR 151, were 
kindly provided by Dr. Mass-Aki Muramatsu (DNAX Research ln- 
stilule of Molecular and Cellular Biology, Palo Alto, CA). EGF-R 
peptidc (Arg-Lys-Arg-Thr-Leu-Arg-Arg-Arg-Leu) was synthesized usitlg 
an automated solid phase synthesizer. An anti-PKC monoclonal an- 
tibody and “‘l-labeled anti-mouse F(ab)r fragment were purchased 
from Amersham Corporation. [y-“P]ATP and [‘Hlphorbol 
12,13-dibutyrate (PDBu) were obtained from DuPont-&w England 
Nuclear. Phosphatidylserine (PS) was purchased from Avanti Polar 
Lipids, Birmingham, AL, phorbol It-myristate 13-acetate (PMA) 
and phorbol 12,13-dibutyrate were from LC Services Corporation, 
Woburn, MA, DEAE-scphacel (DE) was from Whatman. 
2 -2. Tmrsfectiotr of DNA to COS7 cells 
Exponentially growing COS7 cells (I.5 x IO”/10 cm plate, 4 
plates/plasmid) were seeded for 48 h prior lo transduction with 
plasmids. COS7 cells \\ere transfected with plasmids using calcium 
precipitation [S] and cultured at 37°C for 72 h prior to isolation of 
PKC. 
2.3. A~rf~icaliot7 NM/ awt_wls of PKC 
Transfected cells were harvested, washed and homogenized as 
described [5]. Supernatants were applied to DEAE-Sephacel columns 
equilibrated with 20 mM Tris-HCI, pH 7.5, 0.5 mM EDTA, 0.5 mM 
EGTA, 20 mM 2-ME, 100 &I PMSF, IO pg/ml leupeptin and 10% 
glycerol. Wild-type PKCCX was eluted with 100 mM N&l, the mutant 
PKC activities were eluted with 200 mM NaCl [5]. To identify the 
PKC mutants, extracts from COS cells transfecled with these con- 
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Table 1 
Protein kinase activities of PKC mutant constructs 
PKC activity (cpm) 
PKC construct PS+Ca 2~ +TPA EGTA 
SRaPKCa 86 494 2 086 
SR~PKAC 22 484 26 494 
SRaPKCaANS 19 685 21 764 
SR~PKCaACB 23 934 14 984 
SRt~PKCaASB 24 864 27 492 
SRt~PKCaAHH 33 094 4 125 
SRc~PKCaAOP 3 628 2 413 
Aliquots (25 td) of each mutant were assayed for kinase activity using 
EGF'-R (100 taM) as  a substtate and in the presence of I #M PMA, 100 
#M Ca z +, 40/ag/ml phosphatidylserine (PS), 10 #M IT-nP]ATP and 
100/aM EDTA. Activator-independent kinase activity was determined 
in the presence of 1 mM EGTA. PKC activity in the COS-7 ceils was 
14580 cpm. Above values are representative of a typical experiment. 
Fig. 1. Structure of mutant PKC constructs (modified from [51). 
structs were subjected to SDS-polyacrylamide g l electrophoresis [9], 
followed by immunoblot analysis using an anti-PKC antibody (the 
epitope is mapped around residues 296-317 of the wild-type nzyme). 
The mutant enzymes were identified by their altered electrophoretic 
mobilities [51. 
2.4. PKC activity 
PKC activity was measured using EGF-R as a substrate. The reac- 
tion mixture (250 #1) contained 20 mM Tris-HC[, pH 7.5; I0 mM 
Mg(CH3COO)z; 100 /aM CaCI:; I00 #M EGTA; 50 #g/ml 
phosphatidylserine (PS): 1 /aM PMA; 10 #M [7-nP]ATP (1200 
cpm/pmol); I00 #M EGF-R and 100 ng PKC mutant. The mixture 
was incubated at 30°C for 15 rain. Mixtures were removed to an ice- 
bath, a 50 #1 aliquot of each was added to Whatman P81 paper and 
washed in 10% TCA for 20 rain. PKC activity was quantitated by 
liquid scintillation counting. Activator independent kinase activity 
was determined by including 1mM EGTA in the above assay mixture. 
2.5. Phorbol ester binding to intact cells 
Following transfection with the PKC constructs, COS7 cells were 
washed three times with phosphate buffered saline and then incubated 
with 200 #1 assay buffer (50 mM Tris, pH 7.4, and 1 mg/ml bovine 
serum albumin), 100 #l ['~HJPDBu (20 nM final concentration) and 50 
/aM of NPC 15437 or water. The reaction was carried out at 37°C for 
30 rain. Non-specific binding was determined under the same condi- 
tions in the presence of 100 #M non-radioactive PDBu. 
3. RESULTS 
3.1. PKC activity in extracts f rom COS7 cells trans- 
fected with cDNAs  fo r  mutant  PKCs 
Fol lowing partial  pur i f icat ion,  the PKC activity of  
the mutants  was determined using a peptide substrate 
that is specific for PKC [10]. In agreement  with 
previous studies [5], t ransfect ion of COS7 ceils with 
SR~PKCc¢ resulted in a 5-fold increase in PKC activity 
which was dependent  upon  added phosphol ip id ,  Ca 2 + 
and phorbo l  ester (Table  I). Transfect ion with 
SRaPKAC (a mutant  in which amino  acids 1-253 of  
PKC~ are replaced with amino  acids 1-17 of the 
N-terminal  region of PKA) ,  SRaPKCo~ANS or 
SR~PKCc~&SB conferred an increase in prote in  kinase 
act iv ity independent  of phosphol ip id ,  Ca ~ +, and  phor-  
bol  ester. However ,  SRaPKCaACB was still part ial ly 
dependent  on the presence of  the activators for  full ac- 
t iv ity (Table I). SRaPKCaAHH demonstrated protein 
k inase activity that  was dependent  on phosphol ip id,  
Ca z +, and phorbo l  ester. However ,  this protein kinase 
required a much lower concentrat ion  of Ca 2 + for full 
act iv ity than wi ld-type PKC.  
3.2. Interaction o f  NPC 15437 with the mutant  PKC 
molecules 
The interact ion of NPC 15437 with SRocPKC~ and 
SRozPKAC is shown in Fig. 2. Under  condit ions that 
max imal ly  st imulate kinase activity, NPC 15437 in- 
h ib i ted the prote in  kinase activity of  PKCe with an ICso 
value of  22 #M and a Hill coeff ic ient value (n•) of 2, in 
close agreement with our previous study [7]. 
Signif icantly,  NPC 15437 had no effect on the prote in 
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Fig. 2. Interaction of NPC 15437 with SR~PKC~ and SR~PKAC. 
Kinase activities were determined in the presence of 100 #M EGF-R, 
I #M PMA, 50#g/ml PS, 100 /aM Ca 2+, 100/aM EGTA, 10 #M 
[7-nP]ATP and 100 ng PKCo~ p) or PKAC ( I ) .  Activity of PKAC 
was also determined in the presence of 1 mM EGTA. 
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Table II 
Interaction of NPC 15437. staurosporine, and H-7 with SRaPKCk 
and SRcvPKAC 
Go 
Inhibitor PKCol PKAC 
~- 
NPC 15437 22 + 4 jrM - 
Staurosporine 30~t6nM 10 k 4 nM 
H-7 15It_Jprvl 18t5~M 
PKC activity \vas determined as described in Materials and Methods. 
Values represent mean 2 SE OF triplicate determinations in at least 3 
separate experiments. 
kinase activity of SRaPKhC. In contrast, I-I-7 and 
staurosporine, non-selective inhibitors of PKC [ 11,121, 
inhibited both kinase activities (Table II). These studies 
indicate that NPC 15437 interacts with the regulatory 
domain of the enzyme which would account for the 
selectivity observed in our earlier studies. Mutants 
SR~PKCCYANS, SRaPKCaASB, SR~PKC~XACB and 
SR~PKCorAHI-I provided more information concern- 
ing the site of interaction of NPC 15437 with the 
regulatory domain. 
Protein kinase activity of mutants lacking either the 
entire Cl domain (ASB) or a mutant lacking the 
pseudosubstratc binding region and part of the phorbol 
ester binding domain (ANS) was unaffected by the 
presence of NPC 15437 at concentrations up to 200 PM 
(Fig. 3) indicating an interaction between the inhibitor 
and the Cl region of the enzyme deleted in these 
mutants. In contrast, H-7 inhibited the protein kinase 
activity of these mutants with IGO values of 15 FM and 
22 FM, respectively. NPC 15437 readily inhibited the 
kinase activity of AHH (IGO = 30 PM) but was a weak 
inhibitor of ACB (IGo = 130 PM). 
z 
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Fig. 3. Effect of NPC 15437 on the ltinase activity of SRaPKCaANS 
and SRorPKCuASB ( q ), SRaPKCcuACB (&) and SRcuPKCaAHH (0). 
Kinase activities were determined as described in the legend to Fig. 2. 
The ~11 values for the inhibition of SRaPKCaACB and 
SRaPKCaAHH were 1.1 and 1.4, respectively. 
-6 
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Fig. 4. NPC 15437 inhibits [‘HJPDBu binding to PKCrr in intact cells 
(NII = 1.8). Studies were carried out as described in Materials and 
Methods. 
Further evidence for the involvement of the Cl 
region in the interaction of NPC 15437 with PKC came 
from a kinetic analysis of the inhibition with respect to 
activation of the enzyme by phorbol ester. Inhibition 
was largely overcome by increasing concentrations of 
phorbol ester, Lineweaver-Burke and Dixon analysis in- 
dicated that NPC 15437 was a competitive inhibitor of 
the activation by phorbol ester with a Ki value of 5 t 2 
FM. 
3.3. NPC 15437 inhibits f3HJPDBu binding to PKC in 
in tact cells 
Finally, the ability of NPC 15437 to exert an in- 
hibitory effect on phorbol ester binding to PKC in in- 
tact cells was assessed. NPC 15437 dose-dependently 
antagonized phorbol ester binding activity in COS7 
cells transfected with either AOP, a mutant lacking the 
entire catalytic domain of the enzyme, or PKCa (Fig. 4) 
with ICSO values of 19 PM and 27 PM, respectively. H-7 
had no effect on the binding of phorbol ester to AOP. 
4. DISCUSSION 
The mechanism underlying the selective inhibition of 
PKC by NPC 15437 is now becoming better under- 
stood. In a previous report, we demonstrated that this 
synthetically derived compound is a selective inhibitor 
of PKC activity [7]. Mechanistic studies had indicated a 
direct interaction with the regulatory domain most like- 
ly at either the phorbol ester or phospholipid binding 
sites. Significantly, recent evidence indicates that NPC 
15437 is not inhibiting the enzyme via a lipid perturba- 
tion effect (Sullivan, J.P. and Connor, J.R., unpublish- 
ed data). Herein, using recombinant mutant PKC 
molecules, we have shown that NPC 15437 is interac- 
ting with the N-terminal region of the Cl domain. 
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Indirect evidence for this conclusion came from 
studies using AI-II-I and AOP. First, recent observations 
that nPKC, PKCG and PKCe, all of which lack the C2 
domain 1131, require phospholipid and 
diacylglyceroVphorbo1 ester but not Ca2+ for maximal 
activation of the enzyme have suggested that this region 
may regulate the affinity of PKC for CaZC require- 
ment. Since NPC 15437 inhibited the protein kinase as- 
tivity of AWH it is reasonable to assume that the activity 
of this mutant is not dependent on the calcium concen- 
tration. Secondly, NPC 15437 attenuated the binding of 
phorbol ester to PKCa and AOP, demonstrating that 
the presence of the catalytic domain is not critical to the 
inhibitory activity of the compound. The Hill coeffi- 
cient for phorbol ester binding to PKCa was 1.8, con- 
firming that the DAG/phorbol ester binding site 
regulates the enzyme allosterically [ 1,3,16]. Not surpris- 
ingly, H-7, a non-selective inhibitor that interacts at the 
ATP binding site, had no effect on the phorbol ester 
binding to AOP. Deletions in the Cl domain of the en- 
zyme provided more conclusive evidence on the site of 
interaction of NPC 15437 with PKC. 
The Cl region of PKCa has a tandem repeat 
characteristic of a sequence that resembles the cysteine- 
rich zinc-finger motif. Such a sequence motif has been 
identified in many DNA binding proteins that appear to 
be active in transcriptional regulation [14]. While there 
is presently no indication that PKC interacts directly 
with DNA, there is evidence to indicate that these se- 
quences are indispensable for the binding of phorbol 
ester to the enzymes [5,6] and that binding of phorbol 
ester to either of the sequences is sufficient for PKC ac- 
tivation [6]. In addition, the Cl domain contains the 
pseudosubstrate binding region. This stretch of amino 
acids is believed to play a crucial role in the conforma- 
tional changes that result in activation of the enzyme 
[15,16]. We have shown that NPC 15437 has no effect 
on the kinase activity of(i) a mutant lacking both of the 
cysleine-rich sequences, ASB, and (ii) a mutant lacking 
the pseudosubstrate region and part of the first of the 
cysteine repeat sequences, ANS. Interestingly, NPC 
15437 did have some effect on the protein kinase activi- 
ty of ACB, a mutant lacking the second of the cysteine- 
rich sequences that lies between amino acids 104 and 
161 [6]. Taken together with the kinetic analysiS these 
results would suggest that NPC 15437 is interacting 
with the N-terminal region of the Cl domain, a stretch 
of amino acids that includes the pseud0substrat.e r gion 
and part of the first of the cysteine-rich sequences [5,6]. 
Such an interaction may induce conformational 
changes in the enzyme that prevent DAG/phorbol ester 
binding to the enzyme or, more likely, binding of the in- 
hibitor may block the ability of DAG/phorbol ester to 
alter the conformation of PKC in order to activate it. 
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